Markov model input variables (all costs are in US dollars for the year 2013).

DP = Dihydroartemisinin Piperaquine; AL = Artemether-Lumefantrine; SD = Standard Deviation; Max = Maximum; Min = Minimum. aUsing the data reported by a multi-centre trial of ACTs on the number of patients whose treatment was failure free (N) over a follow-up period of 63 days [6], the weekly hazard rates for recurrent malaria following treatment with DHPQ and AL were estimated using Kaplan-Meier estimator as ht = 1−(Nt/Nt-1), where t = 1, 2,…9 weeks. The hazard rate for uncomplicated malarial disease in healthy children was estimated by taking the average of the hazard rates for recurrent malaria at weeks 8 and 9 following treatment with DP and AL. bFor these clinical outcomes, β distributions were calculated based on the incidence of mortality and neurological sequelae in malaria patients as reported in a randomized trail that compared parental treatment with either artesunate or quinine in African children with severe malaria [15], [16].